Inoue Jun, Inazawa Johji
Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Bioresource Research Center, TMDU, Tokyo, Japan.
J Hum Genet. 2021 Sep;66(9):937-945. doi: 10.1038/s10038-021-00938-6. Epub 2021 Jun 4.
MicroRNA (miRNA; miR) is a functionally small non-coding RNA and can negatively regulate gene expression by directly binding to the target gene. Some miRNAs are closely involved in the development and progression of cancer and are abnormally expressed in many cancer types. Therefore, control of the expression of cancer-associated miRNAs is expected as a next-generation drug modality to treat advanced types of cancers with high unmet medical needs. Indeed, miRNA therapeutics, which are based on the functional inhibition of oncogenic miRNA (OncomiR) using antisense oligonucleotides (anti-miR) and the replacement via the introduction of a synthetic miRNA mimic for tumor suppressive miRNA (TS-miR), have been developed. In this review, we summarize cancer-associated miRNAs related to various cancer pathologies and their clinical application to miRNA therapeutics for cancer.
微小RNA(miRNA;miR)是一种具有功能的小非编码RNA,可通过直接结合靶基因来负调控基因表达。一些miRNA与癌症的发生发展密切相关,且在多种癌症类型中异常表达。因此,控制癌症相关miRNA的表达有望成为一种下一代药物模式,用于治疗有高度未满足医疗需求的晚期癌症类型。事实上,已经开发出了基于使用反义寡核苷酸(抗miR)对致癌miRNA(癌基因miRNA)进行功能抑制以及通过引入合成miRNA模拟物来替代肿瘤抑制性miRNA(TS-miR)的miRNA疗法。在本综述中,我们总结了与各种癌症病理相关的癌症相关miRNA及其在癌症miRNA治疗中的临床应用。